Global Pharmacogenomics Technology (Theranostics & CDx) Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Page: 95

Published Date: 23 Nov 2021

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Pharmacogenomics Technology (Theranostics & CDx) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Pharmacogenomics Technology (Theranostics & CDx) size is estimated to be USD 14450 million in 2026 from USD 8525.9 million in 2020, with a change  % between 2020 and 2021. The global Pharmacogenomics Technology (Theranostics & CDx) market size is expected to grow at a CAGR of 14.1% for the next five years.

Market segmentation
Pharmacogenomics Technology (Theranostics & CDx) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    Instrument
    Reagents and Consumables
    Others

Market segment by Application, can be divided into
    Tumor
    Diabetes
    Mental Diseases
    Cardiovascular Diseases
    Others

Market segment by players, this report covers
    Illumina
    Roche
    Agilent
    Abbott
    Thermofisher
    Qiagen
    Guardant Health
    MGI Tech Co., Ltd.
    Amoydx Biology
    Genomics

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Pharmacogenomics Technology (Theranostics & CDx) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Pharmacogenomics Technology (Theranostics & CDx), with revenue, gross margin and global market share of Pharmacogenomics Technology (Theranostics & CDx) from 2019 to 2021.
Chapter 3, the Pharmacogenomics Technology (Theranostics & CDx) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Pharmacogenomics Technology (Theranostics & CDx) market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Pharmacogenomics Technology (Theranostics & CDx) research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Pharmacogenomics Technology (Theranostics & CDx)
    1.2 Classification of Pharmacogenomics Technology (Theranostics & CDx) by Type
        1.2.1 Overview: Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type: 2020 Versus 2021 Versus 2026
        1.2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type in 2020
        1.2.3 Instrument
        1.2.4 Reagents and Consumables
        1.2.5 Others
    1.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market by Application
        1.3.1 Overview: Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application: 2020 Versus 2021 Versus 2026
        1.3.2 Tumor
        1.3.3 Diabetes
        1.3.4 Mental Diseases
        1.3.5 Cardiovascular Diseases
        1.3.6 Others
    1.4 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size & Forecast
    1.5 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast by Region
        1.5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2016 VS 2021 VS 2026
        1.5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region, (2016-2021)
        1.5.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2016-2026)
        1.5.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2016-2026)
        1.5.5 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2016-2026)
        1.5.6 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2016-2026)
        1.5.7 Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2016-2026)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
        1.6.2 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
        1.6.3 Pharmacogenomics Technology (Theranostics & CDx) Trends Analysis

2 Company Profiles
    2.1 Illumina
        2.1.1 Illumina Details
        2.1.2 Illumina Major Business
        2.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
        2.1.4 Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019-2021)
        2.1.5 Illumina Recent Developments and Future Plans
    2.2 Roche
        2.2.1 Roche Details
        2.2.2 Roche Major Business
        2.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
        2.2.4 Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019-2021)
        2.2.5 Roche Recent Developments and Future Plans
    2.3 Agilent
        2.3.1 Agilent Details
        2.3.2 Agilent Major Business
        2.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
        2.3.4 Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019-2021)
        2.3.5 Agilent Recent Developments and Future Plans
    2.4 Abbott
        2.4.1 Abbott Details
        2.4.2 Abbott Major Business
        2.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
        2.4.4 Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019-2021)
        2.4.5 Abbott Recent Developments and Future Plans
    2.5 Thermofisher
        2.5.1 Thermofisher Details
        2.5.2 Thermofisher Major Business
        2.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
        2.5.4 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019-2021)
        2.5.5 Thermofisher Recent Developments and Future Plans
    2.6 Qiagen
        2.6.1 Qiagen Details
        2.6.2 Qiagen Major Business
        2.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
        2.6.4 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019-2021)
        2.6.5 Qiagen Recent Developments and Future Plans
    2.7 Guardant Health
        2.7.1 Guardant Health Details
        2.7.2 Guardant Health Major Business
        2.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
        2.7.4 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019-2021)
        2.7.5 Guardant Health Recent Developments and Future Plans
    2.8 MGI Tech Co., Ltd.
        2.8.1 MGI Tech Co., Ltd. Details
        2.8.2 MGI Tech Co., Ltd. Major Business
        2.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
        2.8.4 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019-2021)
        2.8.5 MGI Tech Co., Ltd. Recent Developments and Future Plans
    2.9 Amoydx Biology
        2.9.1 Amoydx Biology Details
        2.9.2 Amoydx Biology Major Business
        2.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
        2.9.4 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019-2021)
        2.9.5 Amoydx Biology Recent Developments and Future Plans
    2.10 Genomics
        2.10.1 Genomics Details
        2.10.2 Genomics Major Business
        2.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
        2.10.4 Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019-2021)
        2.10.5 Genomics Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue and Share by Players (2019-2021)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share
        3.2.2 Top 10 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share
        3.2.3 Market Competition Trend
    3.3 Pharmacogenomics Technology (Theranostics & CDx) Players Head Office, Products and Services Provided
    3.4 Mergers & Acquisitions
    3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue and Market Share by Type (2016-2021)
    4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Forecast by Type (2021-2026)

5 Market Size Segment by Application
    5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2016-2021)
    5.2 Pharmacogenomics Technology (Theranostics & CDx) Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application
    6.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2016-2026)
    6.2 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2026)
    6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
        6.3.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2016-2026)
        6.3.2 United States Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        6.3.3 Canada Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        6.3.4 Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application
    7.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2016-2026)
    7.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2026)
    7.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
        7.3.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2016-2026)
        7.3.2 Germany Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        7.3.3 France Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        7.3.4 United Kingdom Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        7.3.5 Russia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        7.3.6 Italy Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2016-2026)
    8.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2026)
    8.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region
        8.3.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Region (2016-2026)
        8.3.2 China Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        8.3.3 Japan Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        8.3.4 South Korea Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        8.3.5 India Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        8.3.6 Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        8.3.7 Australia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application
    9.1 South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2016-2026)
    9.2 South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2026)
    9.3 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
        9.3.1 South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2016-2026)
        9.3.2 Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        9.3.3 Argentina Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2016-2026)
    10.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2026)
    10.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
        10.3.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2016-2026)
        10.3.2 Turkey Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        10.3.3 Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)
        10.3.4 UAE Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
    Table 2. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
    Table 3. Global Market Pharmacogenomics Technology (Theranostics & CDx) Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
    Table 4. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) by Region (2016-2021)
    Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Region (2021-2026)
    Table 6. Illumina Corporate Information, Head Office, and Major Competitors
    Table 7. Illumina Major Business
    Table 8. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
    Table 9. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 10. Roche Corporate Information, Head Office, and Major Competitors
    Table 11. Roche Major Business
    Table 12. Roche Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
    Table 13. Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 14. Agilent Corporate Information, Head Office, and Major Competitors
    Table 15. Agilent Major Business
    Table 16. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
    Table 17. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 18. Abbott Corporate Information, Head Office, and Major Competitors
    Table 19. Abbott Major Business
    Table 20. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
    Table 21. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 22. Thermofisher Corporate Information, Head Office, and Major Competitors
    Table 23. Thermofisher Major Business
    Table 24. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
    Table 25. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 26. Qiagen Corporate Information, Head Office, and Major Competitors
    Table 27. Qiagen Major Business
    Table 28. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
    Table 29. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 30. Guardant Health Corporate Information, Head Office, and Major Competitors
    Table 31. Guardant Health Major Business
    Table 32. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
    Table 33. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 34. MGI Tech Co., Ltd. Corporate Information, Head Office, and Major Competitors
    Table 35. MGI Tech Co., Ltd. Major Business
    Table 36. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
    Table 37. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 38. Amoydx Biology Corporate Information, Head Office, and Major Competitors
    Table 39. Amoydx Biology Major Business
    Table 40. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
    Table 41. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 42. Genomics Corporate Information, Head Office, and Major Competitors
    Table 43. Genomics Major Business
    Table 44. Genomics Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions
    Table 45. Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 46. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) by Players (2019-2021)
    Table 47. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Players (2019-2021)
    Table 48. Breakdown of Pharmacogenomics Technology (Theranostics & CDx) by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 49. Pharmacogenomics Technology (Theranostics & CDx) Players Head Office, Products and Services Provided
    Table 50. Pharmacogenomics Technology (Theranostics & CDx) Mergers & Acquisitions in the Past Five Years
    Table 51. Pharmacogenomics Technology (Theranostics & CDx) New Entrants and Expansion Plans
    Table 52. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) by Type (2016-2021)
    Table 53. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2016-2021)
    Table 54. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Forecast by Type (2021-2026)
    Table 55. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2021)
    Table 56. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Forecast by Application (2021-2026)
    Table 57. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2016-2021) & (USD Million)
    Table 58. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (USD Million)
    Table 59. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2021) & (USD Million)
    Table 60. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (USD Million)
    Table 61. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2016-2021) & (USD Million)
    Table 62. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026) & (USD Million)
    Table 63. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2016-2021) & (USD Million)
    Table 64. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (USD Million)
    Table 65. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2021) & (USD Million)
    Table 66. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (USD Million)
    Table 67. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2016-2021) & (USD Million)
    Table 68. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026) & (USD Million)
    Table 69. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2016-2021) & (USD Million)
    Table 70. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (USD Million)
    Table 71. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2021) & (USD Million)
    Table 72. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (USD Million)
    Table 73. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Region (2016-2021) & (USD Million)
    Table 74. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Region (2021-2026) & (USD Million)
    Table 75. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2016-2021) & (USD Million)
    Table 76. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (USD Million)
    Table 77. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2021) & (USD Million)
    Table 78. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (USD Million)
    Table 79. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2016-2021) & (USD Million)
    Table 80. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026) & (USD Million)
    Table 81. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2016-2021) & (USD Million)
    Table 82. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2021-2026) & (USD Million)
    Table 83. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2016-2021) & (USD Million)
    Table 84. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2021-2026) & (USD Million)
    Table 85. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2016-2021) & (USD Million)
    Table 86. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2021-2026) & (USD Million)
List of Figures
    Figure 1. Pharmacogenomics Technology (Theranostics & CDx) Picture
    Figure 2. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type in 2020
    Figure 3. Instrument
    Figure 4. Reagents and Consumables
    Figure 5. Others
    Figure 6. Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application in 2020
    Figure 7. Tumor Picture
    Figure 8. Diabetes Picture
    Figure 9. Mental Diseases Picture
    Figure 10. Cardiovascular Diseases Picture
    Figure 11. Others Picture
    Figure 12. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue, (USD Million): 2020 VS 2021 VS 2026
    Figure 13. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue and Forecast (2016-2026) & (USD Million)
    Figure 14. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Region (2016-2026)
    Figure 15. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Region in 2020
    Figure 16. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 17. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 18. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 19. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 20. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 21. Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
    Figure 22. Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
    Figure 23. Pharmacogenomics Technology (Theranostics & CDx) Market Trends
    Figure 24. Illumina Recent Developments and Future Plans
    Figure 25. Roche Recent Developments and Future Plans
    Figure 26. Agilent Recent Developments and Future Plans
    Figure 27. Abbott Recent Developments and Future Plans
    Figure 28. Thermofisher Recent Developments and Future Plans
    Figure 29. Qiagen Recent Developments and Future Plans
    Figure 30. Guardant Health Recent Developments and Future Plans
    Figure 31. MGI Tech Co., Ltd. Recent Developments and Future Plans
    Figure 32. Amoydx Biology Recent Developments and Future Plans
    Figure 33. Genomics Recent Developments and Future Plans
    Figure 34. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Players in 2020
    Figure 35. Pharmacogenomics Technology (Theranostics & CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    Figure 36. Global Top 3 Players Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share in 2020
    Figure 37. Global Top 10 Players Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share in 2020
    Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
    Figure 39. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type in 2020
    Figure 40. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Type (2021-2026)
    Figure 41. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application in 2020
    Figure 42. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Application (2021-2026)
    Figure 43. North America Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Type (2016-2026)
    Figure 44. North America Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Application (2016-2026)
    Figure 45. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Country (2016-2026)
    Figure 46. United States Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 47. Canada Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 48. Mexico Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 49. Europe Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Type (2016-2026)
    Figure 50. Europe Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Application (2016-2026)
    Figure 51. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Country (2016-2026)
    Figure 52. Germany Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 53. France Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 54. United Kingdom Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 55. Russia Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 56. Italy Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 57. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Type (2016-2026)
    Figure 58. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Application (2016-2026)
    Figure 59. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Region (2016-2026)
    Figure 60. China Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 61. Japan Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 62. South Korea Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 63. India Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 64. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 65. Australia Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 66. South America Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Type (2016-2026)
    Figure 67. South America Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Application (2016-2026)
    Figure 68. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Country (2016-2026)
    Figure 69. Brazil Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 70. Argentina Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 71. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Type (2016-2026)
    Figure 72. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Application (2016-2026)
    Figure 73. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Country (2016-2026)
    Figure 74. Turkey Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 75. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 76. UAE Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 77. Methodology
    Figure 78. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Illumina
Roche
Agilent
Abbott
Thermofisher
Qiagen
Guardant Health
MGI Tech Co., Ltd.
Amoydx Biology
Genomics

Related Reports

Global Pharmacogenomics Technology (Theranostics & CDx) Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global Pharmacogenomics Technology (Theranostics & CDx) Market 2022 by Company, Regions, Type and Application, Forecast to 2028

date 04 Jan 2022

date Medical Care

The Pharmacogenomics Technology (Theranostics & CDx) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Product Tags

pharmacogenomics technology theranostics cdx

Pharmacogenomics Technology (Theranostics & CDx)

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>